NEW YORK, Dec. 15, 2015 (GLOBE NEWSWIRE) -- Lion
Biotechnologies (Nasdaq:LBIO), a biotechnology company that is
developing novel cancer immunotherapies based on tumor-infiltrating
lymphocytes (TIL), today announced that it has been selected for
addition to the NASDAQ Biotechnology Index effective December 21, 2015.
The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). These companies must meet eligibility requirements, including minimum market capitalization, average daily trading volume, and seasoning as a public company, among other criteria. The index is re-ranked annually and serves as the basis for the iShares NASDAQ Biotechnology Index Fund. For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit https://indexes.nasdaqomx.com.
About Lion Biotechnologies
Lion Biotechnologies, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) for the treatment of patients with refractory metastatic melanoma, and is based on a clinical Cooperative Research and Development Agreement with the National Cancer Institute. TIL therapy is also being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and Moffitt Cancer Center. For more information, please visit www.lionbio.com.
Investor Relations The Trout Group Elizabeth Broder 646-378-2945 Ebroder@troutgroup.com
Released December 15, 2015